DOI QR코드

DOI QR Code

Secreotory Leukocyte Protease Inhibitor Regulates Bone Formation via RANKL, OPG, and Runx2 in Rat Periodontitis and MC3T3-E1 Preosteoblast

  • Seung-Yeon Lee (Department of Oral Histology and Developmental Biology, College of Dentistry, Chosun University) ;
  • Soon-Jeong Jeong (Department of Dental Hygiene and Institute of Basic Science for Well-Aging, College of Health Science, Youngsan University) ;
  • Myoung-Hwa Lee (Department of Oral Histology and Developmental Biology, College of Dentistry, Chosun University) ;
  • Se-Hyun Hwang (Department of Dental Hygiene, Yeungnam College) ;
  • Do-Seon Lim (Department of Dental Hygiene, College of Health Science, Eulji University) ;
  • Moon-Jin Jeong (Department of Oral Histology and Developmental Biology, College of Dentistry, Chosun University)
  • Received : 2023.10.31
  • Accepted : 2023.11.21
  • Published : 2023.12.31

Abstract

Background: Secretory leukocyte protease inhibitor (SLPI) protects tissues from proteases and promotes cell proliferation and healing. SLPI also reduces periodontal inflammation and alveolar bone resorption by inhibiting proinflammatory cytokine expression in rat periodontal tissues and osteoblasts. However, little is known of the role of SLPI in the expression of osteoclast regulatory factors from osteoblasts, which are crucial for the interaction between osteoblasts and osteoclasts. Therefore, we aimed to determine the effects of SLPI on the regulation of osteoclasts and osteoblasts in LPS-treated alveolar bone and osteoblasts. Methods: Periodontitis was induced in rats using LPS. After each LPS injection, SLPI was injected into the same area. Immunohistochemical analysis was performed with antibodies against SLPI, RANKL, OPG, and Runx2 in the periodontal tissue. RT-PCR and western blotting were performed to determine the expression levels of SLPI, RANKL, OPG, and Runx2 in LPS- and SLPI/LPS-treated MC3T3-E1 cells. SLPI/LPS-treated MC3T3-E1 cells were also stained with Alizarin Red S. Results: Immunohistochemical analysis showed that the expression levels of SLPI, OPG, and Runx2 were higher while that of RANKL was lower in the LPS/SLPI group relative to those in the LPS group. The mRNA and protein expression of SLPI, OPG, and Runx2 was higher in SLPI/LPS/MC3T3-E1 cells than in LPS/MC3T3-E1 cells, and RANKL expression was lower. During differentiation, OPG and Runx2 protein levels were higher whereas RANKL levels were lower in SLPI/LPS/MC3T3-E1 than in LPS/MC3T3-E1 cells on days 0, 4, 7, and 10. In addition, mineralization and matrix deposition were higher in SLPI/LPS/MC3T3-E1 than in LPS/MC3T3-E1 on days 7 and 10. SLPI decreased RANKL expression in LPS-treated alveolar bone and osteoblasts but increased the expression of OPG and Runx2. Conclusion: SLPI can be considered as a regulatory molecule that indirectly regulates osteoclast activation via osteoblasts and promotes osteoblast differentiation.

Keywords

Acknowledgement

This study was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2017R1D1A1B03028872).

References

  1. Lee JW, Asai M, Jeon SK, et al.: Rosmarinic acid exerts an antiosteoporotic effect in the RANKL-induced mouse model of bone loss by promotion of osteoblastic differentiation and inhibition of osteoclastic differentiation. Mol Nutr Food Res 59: 386-400, 2015. https://doi.org/10.1002/mnfr.201400164
  2. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357, 1999. https://doi.org/10.1210/edrv.20.3.0367
  3. Graves D: Cytokines that promote periodontal tissue destruction. J Periodontol 79(8 Suppl): 1585-1591, 2008. https://doi.org/10.1902/jop.2008.080183
  4. Inubushi T, Kawazoe A, Miyauchi M, et al.: Molecular mechanisms of the inhibitory effects of bovine lactoferrin on lipopolysaccharide-mediated osteoclastogenesis. J Biol Chem 287: 23527-23536, 2012. https://doi.org/10.1074/jbc.M111.324673
  5. Yasuda H, Shima N, Nakagawa N, et al.: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329-1337, 1998. https://doi.org/10.1210/endo.139.3.5837
  6. Xu Y, Jiang Z, Ji G, Liu J: Inhibition of bone metastasis from breast carcinoma by rosmarinic acid. Planta Med 76: 956-962, 2010. https://doi.org/10.1055/s-0029-1240893
  7. Wachi T, Shuto T, Shinohara Y, Matono Y, Makihira S: Release of titanium ions from an implant surface and their effect on cytokine production related to alveolar bone resorption. Toxicology 327: 1-9, 2015. https://doi.org/10.1016/j.tox.2014.10.016
  8. Lacey DL, Timms E, Tan HL, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998. https://doi.org/10.1016/s0092-8674(00)81569-x
  9. Deyama Y, Takeyama S, Koshikawa M, et al.: Osteoblast maturation suppressed osteoclastogenesis in coculture with bone marrow cells. Biochem Biophys Res Commun 274: 249-254, 2000. https://doi.org/10.1006/bbrc.2000.3127
  10. Simonet WS, Lacey DL, Dunstan CR, et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997. https://doi.org/10.1016/s0092-8674(00)80209-3
  11. Komori T: Regulation of osteoblast differentiation by Runx2. Adv Exp Med Biol 658: 43-49, 2010. https://doi.org/10.1007/978-1-4419-1050-9_5
  12. Komori T: Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 99: 1233-1239, 2006. https://doi.org/10.1002/jcb.20958
  13. Jeong SJ, Choi BD, Lee HY, et al.: 660 nm red LED induces secretory leukocyte protease inhibitor (SLPI) in lipopolysaccharide-stimulated Raw264.7 cell. J Nanosci Nanotechnol 15: 5610-5616, 2015. https://doi.org/10.1166/jnn.2015.10465
  14. Choi BD, Jeong SJ, Wang G, et al.: Temporal induction of secretory leukocyte protease inhibitor (SLPI) in odontoblasts by lipopolysaccharide and wound infection. J Endod 35: 997-1002, 2009. https://doi.org/10.1016/j.joen.2009.04.008
  15. Jeong JO, Wang G, Jeong SJ, Choi BD, Lee HY, Jeong MJ: Function of secretory leukocyte protease inhibitor (SLPI) in odontoblast during mouse tooth development. J Nanosci Nanotechnol 15: 120-124, 2015. https://doi.org/10.1166/jnn.2015.8384
  16. Jeong SJ, Wang G, Choi BD, et al.: Secretory leukocyte protease inhibitor (SLPI) increases focal adhesion in MC3T3 osteoblast on titanium surface. J Nanosci Nanotechnol 15: 200-204, 2015. https://doi.org/10.1166/jnn.2015.8383
  17. Choi BD, Lee SY, Jeong SJ, et al.: Secretory leukocyte protease inhibitor promotes differentiation and mineralization of MC3T3-E1 preosteoblasts on a titanium surface. Mol Med Rep 14: 1241-1246, 2016. https://doi.org/10.3892/mmr.2016.5381
  18. Lee SY, Nho TH, Choi BD, Jeong SJ, Lim DS, Jeong MJ: Secretory leukocyte protease inhibitor reduces inflammation and alveolar bone resorption in LPS-induced periodontitis in rats and in MC3T3-E1 preosteoblasts. Anim Cells Syst 20: 344-352, 2016. https://doi.org/10.1080/19768354.2016.1250817
  19. Lindemann RA, Economou JS, Rothermel H: Production of interleukin-1 and tumor necrosis factor by human peripheral monocytes activated by periodontal bacteria and extracted lipopolysaccharides. J Dent Res 67: 1131-1135, 1988. https://doi.org/10.1177/00220345880670081401
  20. Gabay C, Lamacchia C, Palmer G: IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6: 232-241, 2010. https://doi.org/10.1038/nrrheum.2010.4
  21. Hiemstra PS: Novel roles of protease inhibitors in infection and inflammation. Biochem Soc Trans 30: 116-120, 2002. https://doi.org/10.1042/bst0300116
  22. Williams SE, Brown TI, Roghanian A, Sallenave JM: SLPI and elafin: one glove, many fingers. Clin Sci (Lond) 110: 21-35, 2006. https://doi.org/10.1042/CS20050115
  23. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL: The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15: 2-12, 2000. https://doi.org/10.1359/jbmr.2000.15.1.2
  24. Jeong MJ, Lim DS, Kim SO, Park C, Choi YH, Jeong SJ: Effect of rosmarinic acid on differentiation and mineralization of MC3T3-E1 osteoblastic cells on titanium surface. Anim Cells Syst (Seoul) 25: 46-55, 2021. https://doi.org/10.1080/19768354.2021.1886987
  25. Gilbert L, He X, Farmer P, et al.: Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 277: 2695-2701, 2002. https://doi.org/10.1074/jbc.M106339200 
  26. Chen X, Wang Z, Duan N, Zhu G, Schwarz EM, Xie C: Osteoblast-osteoclast interactions. Connect Tissue Res 59: 99-107, 2018. https://doi.org/10.1080/03008207.2017.1290085
  27. Siddiqui S, Mahdi AA, Arshad M: Genistein contributes to cell cycle progression and regulates oxidative stress in primary culture of osteoblasts along with osteoclasts attenuation. BMC Complement Med Ther 20: 277, 2020. https://doi.org/10.1186/s12906-020-03065-5
  28. Lai K, Xi Y, Du X, et al.: Activation of Nell-1 in BMSC sheet promotes implant osseointegration through regulating Runx2/ Osterix axis. Front Cell Dev Biol 8: 868, 2020. https://doi.org/10.3389/fcell.2020.00868
  29. Yu SB, Kim HJ, Kang HM, Park BS, Lee JH, Kim IR: Cordycepin accelerates osteoblast mineralization and attenuates osteoclast differentiation in vitro. Evid Based Complement Alternat Med 2018: 5892957, 2018. https://doi.org/10.1155/2018/5892957
  30. Kim JH, Kim M, Jung HS, Sohn Y: Leonurus sibiricus L. ethanol extract promotes osteoblast differentiation and inhibits osteoclast formation. Int J Mol Med 44: 913-926, 2019. https://doi.org/10.3892/ijmm.2019.4269
  31. Kruger EA, Im DD, Bischoff DS, et al.: In vitro mineralization of human mesenchymal stem cells on threedimensional type I collagen versus PLGA scaffolds: a comparative analysis. Plast Reconstr Surg 127: 2301-2311, 2011. https://doi.org/10.1097/PRS.0b013e318213a004